ADRXADARx Pharmaceuticals, Inc.Signing up patients
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Geographic Atrophy Secondary to Age-related Macular Degeneration
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 240 (planned)
- Started
- Nov 10, 2025
- Main results expected
- Feb 28, 2030
- Fully finished
- Aug 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Evaluate the effect of ADX-038 on the preservation of the EZ layer
Measured over: 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06990269 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC